MX2022001961A - Medio de cultivo para induccion de hematopoyesis. - Google Patents
Medio de cultivo para induccion de hematopoyesis.Info
- Publication number
- MX2022001961A MX2022001961A MX2022001961A MX2022001961A MX2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A MX 2022001961 A MX2022001961 A MX 2022001961A
- Authority
- MX
- Mexico
- Prior art keywords
- signaling pathways
- mediated signaling
- stimulate
- media
- cells
- Prior art date
Links
- 230000011132 hemopoiesis Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 239000001963 growth medium Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 abstract 5
- 230000019491 signal transduction Effects 0.000 abstract 5
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 2
- 102000036693 Thrombopoietin Human genes 0.000 abstract 2
- 108010041111 Thrombopoietin Proteins 0.000 abstract 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 abstract 2
- 108091008605 VEGF receptors Proteins 0.000 abstract 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 2
- 210000003566 hemangioblast Anatomy 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911955.1A GB201911955D0 (en) | 2019-08-20 | 2019-08-20 | Culture medium for haematopoietic induction |
| GBGB2012306.3A GB202012306D0 (en) | 2020-08-07 | 2020-08-07 | Culture medium for haematopoietic induction |
| PCT/EP2020/073407 WO2021032855A1 (en) | 2019-08-20 | 2020-08-20 | Culture medium for haematopoietic induction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001961A true MX2022001961A (es) | 2022-03-11 |
Family
ID=72234836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001961A MX2022001961A (es) | 2019-08-20 | 2020-08-20 | Medio de cultivo para induccion de hematopoyesis. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220275335A1 (enExample) |
| EP (1) | EP4017969A1 (enExample) |
| JP (1) | JP2022545415A (enExample) |
| KR (1) | KR20220047375A (enExample) |
| CN (1) | CN114341349A (enExample) |
| AU (1) | AU2020333918A1 (enExample) |
| BR (1) | BR112022003083A2 (enExample) |
| CA (1) | CA3150037A1 (enExample) |
| IL (1) | IL290602A (enExample) |
| MX (1) | MX2022001961A (enExample) |
| WO (1) | WO2021032855A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| GB202102297D0 (en) * | 2021-02-18 | 2021-04-07 | Adaptimmune Ltd | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
| WO2022241558A1 (en) * | 2021-05-18 | 2022-11-24 | The University Of British Columbia | A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| GB202208545D0 (en) | 2022-06-10 | 2022-07-27 | Adaptimmune Ltd | Production of immune cells |
| WO2024050534A2 (en) * | 2022-09-01 | 2024-03-07 | Regents Of The University Of Minnesota | In vitro generated hematopoietic stem progenitor cells and t cells and methods of making and using the same |
| KR102566680B1 (ko) * | 2022-09-28 | 2023-08-14 | (주)포에버엔케이 | 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도 |
| WO2024107010A1 (ko) * | 2022-11-17 | 2024-05-23 | 주식회사 씨티셀즈 | 미분화 줄기세포로부터 자연 살해 세포로의 분화 방법 및 이의 용도 |
| CN118360247A (zh) * | 2023-01-19 | 2024-07-19 | 中国科学院动物研究所 | 一种iSCLP细胞及其制备方法和应用 |
| GB202318950D0 (en) | 2023-12-12 | 2024-01-24 | Adaptimmune Ltd | Production of immune cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507275TA (en) * | 2013-03-13 | 2015-10-29 | Wisconsin Alumni Res Found | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions |
| JPWO2015199127A1 (ja) * | 2014-06-24 | 2017-04-20 | 国立大学法人京都大学 | 中胚葉細胞および造血細胞の製造方法 |
| WO2016123100A1 (en) * | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| ES2862676T3 (es) * | 2015-10-20 | 2021-10-07 | Fujifilm Cellular Dynamics Inc | Producción de células precursoras hematopoyéticas multilinaje mediante programación genética |
| WO2017078807A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| US12270050B2 (en) * | 2015-12-08 | 2025-04-08 | Regents Of The University Of Minnesota | Human T cell derived from T cell-derived induced pluripotent stem cell and methods of making and using |
| US11141471B2 (en) * | 2016-04-25 | 2021-10-12 | Regen BioPharma, Inc. | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells |
| WO2017193177A1 (en) * | 2016-05-13 | 2017-11-16 | Murdoch Childrens Research Institute | Haematopoietic stem/progenitor cells |
| US20200080058A1 (en) * | 2017-03-21 | 2020-03-12 | Etablissement Francais Du Sang | Methods of improving hematopoietic grafts |
| CN112041428B (zh) * | 2018-01-18 | 2024-05-24 | 新加坡科技研究局 | 用于在悬浮培养物中分化人多能干细胞系的方法 |
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
-
2020
- 2020-08-20 MX MX2022001961A patent/MX2022001961A/es unknown
- 2020-08-20 CN CN202080059143.3A patent/CN114341349A/zh active Pending
- 2020-08-20 EP EP20761198.9A patent/EP4017969A1/en not_active Withdrawn
- 2020-08-20 BR BR112022003083A patent/BR112022003083A2/pt unknown
- 2020-08-20 KR KR1020227009201A patent/KR20220047375A/ko active Pending
- 2020-08-20 CA CA3150037A patent/CA3150037A1/en active Pending
- 2020-08-20 JP JP2022510803A patent/JP2022545415A/ja active Pending
- 2020-08-20 US US17/630,880 patent/US20220275335A1/en not_active Abandoned
- 2020-08-20 AU AU2020333918A patent/AU2020333918A1/en not_active Abandoned
- 2020-08-20 WO PCT/EP2020/073407 patent/WO2021032855A1/en not_active Ceased
-
2022
- 2022-02-14 IL IL290602A patent/IL290602A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220275335A1 (en) | 2022-09-01 |
| JP2022545415A (ja) | 2022-10-27 |
| IL290602A (en) | 2022-04-01 |
| WO2021032855A1 (en) | 2021-02-25 |
| BR112022003083A2 (pt) | 2022-08-02 |
| AU2020333918A1 (en) | 2022-03-24 |
| CN114341349A (zh) | 2022-04-12 |
| CA3150037A1 (en) | 2021-02-25 |
| KR20220047375A (ko) | 2022-04-15 |
| EP4017969A1 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003083A2 (pt) | Meio de cultura para indução hematopoiética | |
| Cany et al. | Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer | |
| Lian et al. | Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling | |
| Sun et al. | Mesenchymal stem cells from patients with rheumatoid arthritis display impaired function in inhibiting Th17 cells | |
| Guihard et al. | Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling | |
| Huang et al. | Effects of shear stress on differentiation of stem cells into endothelial cells | |
| Vodyanik et al. | A mesoderm-derived precursor for mesenchymal stem and endothelial cells | |
| Sim et al. | The IL-2 cytokine family in cancer immunotherapy | |
| Alizadeh et al. | The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer | |
| Kudo-Saito et al. | Induction of immunoregulatory CD271+ cells by metastatic tumor cells that express human endogenous retrovirus H | |
| Wu et al. | Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs | |
| Cutolo et al. | Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. | |
| CN105209609B (zh) | 用于限定条件下的人多潜能干细胞的血内皮分化的方法和材料 | |
| Desplat et al. | Hypoxia modifies proliferation and differentiation of CD34+ CML cells | |
| Castellone et al. | RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2) | |
| Ribatti et al. | Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis | |
| Pellegrino et al. | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target | |
| Nowwarote et al. | Role of endogenous basic fibroblast growth factor in stem cells isolated from human exfoliated deciduous teeth | |
| Lepletier et al. | Perspectives for improvement of the thymic microenvironment through manipulation of thymic epithelial cells: a mini-review | |
| Cubitt et al. | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells | |
| Forget et al. | Stimulation of Wnt/ss-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype | |
| Zheng et al. | Opposite effects of coinjection and distant injection of mesenchymal stem cells on breast tumor cell growth | |
| Zhao et al. | Signaling networks in the control of pluripotency | |
| Michaud et al. | Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3 | |
| Klein Wolterink et al. | The intrathymic crossroads of T and NK cell differentiation |